Bicycle Therapeutics (BCYC)
NASDAQ:BCYC
BCYC Stock Chart & Stats
$4.50
-$0.24(-1.59%)
At close: 4:00 PM EST
$4.50
-$0.24(-1.59%)
Day’s Range― - ―
52-Week Range$4.25 - $9.69
Previous CloseN/A
Volume92.63K
Average Volume (3M)409.04K
Market Cap
$301.06M
Enterprise Value-$286.45M
Total Cash (Recent Filing)$628.11M
Total Debt (Recent Filing)$17.52M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Apr 30, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding50,269,080
10 Day Avg. Volume558,980
30 Day Avg. Volume409,042
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap-0.95
Enterprise Value/Revenue-3.95
Enterprise Value/Gross Profit3.16
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$14.80Price Target Upside228.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.73
Revenue Forecast (FY)$30.53M
Bulls Say, Bears Say
Bulls Say
Clinical SafetyDuravelo-2 initial results indicated a favorable safety profile with very few treatment discontinuations and response rates comparable to an approved therapy, which could bolster confidence in the program's tolerability ahead of future studies.
Operational RestructuringManagement instituted a major reorganization to substantially cut operating costs and concentrate resources on the BT5528 conjugate program, which may extend cash runway and prioritize high-potential assets.
Radiopharmaceutical Pipeline ValueStrong acquisition activity in radiopharmaceuticals and validation of the Bicycle platform suggest the company's radiopharma pipeline may be undervalued as programs advance toward first-in-human studies and strategic partnerships mature.
Bears Say
Development DelaysConversion of the Duravelo program into a later-stage trial to gather additional data and finalize a pivotal study design is expected to delay development timelines and push back key approval milestones.
Leadership And Execution RiskMultiple senior leadership changes, including a new chief financial officer and medical promotions, have raised questions about dose selection and the durability of lead drug candidates, increasing execution and oversight risk.
Loss Of Lead AssetDiscontinuation of zelenectide removed the prior lead clinical asset and eliminated an accelerated approval pathway, reducing near-term clinical catalysts and investor visibility into near-term value drivers.
Bicycle Therapeutics News
BCYC FAQ
What was Bicycle Therapeutics’s price range in the past 12 months?
Bicycle Therapeutics lowest stock price was $4.25 and its highest was $9.69 in the past 12 months.
What is Bicycle Therapeutics’s market cap?
Bicycle Therapeutics’s market cap is $301.06M.
When is Bicycle Therapeutics’s upcoming earnings report date?
Bicycle Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 34 days.
How were Bicycle Therapeutics’s earnings last quarter?
Bicycle Therapeutics released its earnings results on Mar 17, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.937 by $0.647.
Is Bicycle Therapeutics overvalued?
According to Wall Street analysts Bicycle Therapeutics’s price is currently Undervalued.
Does Bicycle Therapeutics pay dividends?
Bicycle Therapeutics does not currently pay dividends.
What is Bicycle Therapeutics’s EPS estimate?
Bicycle Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Bicycle Therapeutics have?
Bicycle Therapeutics has 50,269,080 shares outstanding.
What happened to Bicycle Therapeutics’s price movement after its last earnings report?
Bicycle Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.937. Following the earnings report the stock price went up 0.396%.
Which hedge fund is a major shareholder of Bicycle Therapeutics?
Currently, no hedge funds are holding shares in BCYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicycle Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.80 (228.89% Upside)
$14.80 (228.89% Upside)
Blogger Sentiment
Bearish
BCYC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 137.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $316.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.11%
12-Months-Change
Fundamentals
Return on Equity
-33.20%
Trailing 12-Months
Asset Growth
-25.01%
Trailing 12-Months
Company Description
Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC Stock 12 Month Forecast
Average Price Target
$14.80
▲(228.89% Upside)
Technical Analysis
Ownership Overview
23.12% Insiders
5.85% Mutual Funds
60.09% Other Institutional Investors
10.02% Public Companies and
Individual Investors